Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 09  •  04:00PM ET
188.01
Dollar change
-5.02
Percentage change
-2.60
%
Index- P/E31.22 EPS (ttm)6.02 Insider Own4.81% Shs Outstand1.55B Perf Week-0.21%
Market Cap291.50B Forward P/E18.28 EPS next Y10.29 Insider Trans0.00% Shs Float1.48B Perf Month-0.26%
Enterprise Value316.04B PEG1.52 EPS next Q2.11 Inst Own53.84% Short Float- Perf Quarter13.55%
Income9.40B P/S5.01 EPS this Y11.73% Inst Trans-2.58% Short Ratio- Perf Half Y32.49%
Sales58.13B P/B6.35 EPS next Y12.12% ROA8.57% Short Interest- Perf YTD7.13%
Book/sh29.60 P/C35.63 EPS next 5Y12.06% ROE21.70% 52W High195.00 -3.58% Perf Year44.62%
Cash/sh5.28 P/FCF22.26 EPS past 3/5Y285.86% 34.63% ROIC13.06% 52W Low122.26 53.78% Perf 3Y51.80%
Dividend Est.3.23 (1.72%) EV/EBITDA16.40 Sales past 3/5Y12.64% 17.27% Gross Margin73.23% Volatility2.87% 2.92% Perf 5Y71.78%
Dividend TTM3.16 (1.68%) EV/Sales5.44 EPS Y/Y TTM44.64% Oper. Margin21.86% ATR (14)6.61 Perf 10Y339.79%
Dividend Ex-DateAug 08, 2025 Quick Ratio0.69 Sales Y/Y TTM13.52% Profit Margin16.17% RSI (14)52.76 Recom1.66
Dividend Gr. 3/5Y2.80% 2.47% Current Ratio0.88 EPS Q/Q77.36% SMA201.27% Beta0.39 Target Price221.19
Payout69.15% Debt/Eq0.71 Sales Q/Q11.99% SMA502.09% Rel Volume10.73 Prev Close193.03
Employees94300 LT Debt/Eq0.57 EarningsFeb 10 BMO SMA20018.23% Avg Volume282.26K Price188.01
IPOOct 17, 2003 Option/ShortYes / Yes EPS/Sales Surpr.3.81% 2.79% Trades Volume3,029,286 Change-2.60%
Feb-09-26 07:00PM
11:38AM
10:44AM
09:39AM
09:24AM
09:11AM Loading…
09:11AM
07:16AM
02:30AM
Feb-06-26 07:00PM
06:45PM
05:13PM
11:58AM
08:00AM
07:08AM
06:30AM
12:13AM Loading…
12:13AM
Feb-05-26 09:17PM
09:15AM
08:48AM
08:31AM
Feb-04-26 12:30PM
12:29PM
10:19AM
10:11AM
Feb-03-26 06:15PM
02:30PM
11:48AM
11:36AM
11:34AM
11:02AM
07:00AM Loading…
07:00AM
06:55AM
05:11AM
04:34AM
02:42AM
Feb-02-26 02:15PM
02:04PM
12:29PM
11:00AM
07:00AM
02:46AM
Jan-30-26 12:28PM
11:11AM
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.